Syndax Pharmaceuticals Inc (SNDX) - Total Assets
Based on the latest financial reports, Syndax Pharmaceuticals Inc (SNDX) holds total assets worth $703.65 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Syndax Pharmaceuticals Inc - Total Assets Trend (2011–2025)
This chart illustrates how Syndax Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Syndax Pharmaceuticals Inc (SNDX) market capitalisation for the company's overall valuation and market capitalisation.
Syndax Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Syndax Pharmaceuticals Inc's total assets of $703.65 Million consist of 99.7% current assets and 0.3% non-current assets. Review Syndax Pharmaceuticals Inc (SNDX) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.5% |
| Accounts Receivable | $70.29 Million | 13.3% |
| Inventory | $32.75 Million | 6.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Syndax Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Syndax Pharmaceuticals Inc share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Syndax Pharmaceuticals Inc's current assets represent 99.7% of total assets in 2025, an increase from 91.8% in 2011.
- Cash Position: Cash and equivalents constituted 25.5% of total assets in 2025, down from 77.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 13.3% of total assets.
Syndax Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Syndax Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Syndax Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.77 | 4.71 | 8.30 |
| Quick Ratio | 6.44 | 4.55 | 8.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $575.36 Million | $418.69 Million | $209.54 Million |
Syndax Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Syndax Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 120.47 |
| Latest Market Cap to Assets Ratio | 2.91 |
| Asset Growth Rate (YoY) | -26.9% |
| Total Assets | $529.71 Million |
| Market Capitalization | $1.54 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Syndax Pharmaceuticals Inc's assets at a significant premium (2.91x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Syndax Pharmaceuticals Inc's assets decreased by 26.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Syndax Pharmaceuticals Inc (2011–2025)
The table below shows the annual total assets of Syndax Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $529.71 Million | -26.92% |
| 2024-12-31 | $724.82 Million | +18.26% |
| 2023-12-31 | $612.88 Million | +23.26% |
| 2022-12-31 | $497.24 Million | +10.58% |
| 2021-12-31 | $449.66 Million | +49.58% |
| 2020-12-31 | $300.61 Million | +373.22% |
| 2019-12-31 | $63.52 Million | -24.32% |
| 2018-12-31 | $83.94 Million | -38.81% |
| 2017-12-31 | $137.19 Million | +25.84% |
| 2016-12-31 | $109.01 Million | +21.26% |
| 2015-12-31 | $89.90 Million | +601.49% |
| 2014-12-31 | $12.82 Million | -24.88% |
| 2013-12-31 | $17.06 Million | +1029.87% |
| 2012-12-31 | $1.51 Million | -68.45% |
| 2011-12-31 | $4.79 Million | -- |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. Th… Read more